Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
The group’s point-of-care Car-T push looks to have stalled.
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
